Serum Periostin as a Biomarker for Breast Cancer Diagnosis and Metastasis Prediction | ||||
| Zagazig University Medical Journal | ||||
| Articles in Press, Accepted Manuscript, Available Online from 27 July 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2025.382786.3940 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amira Raafat Elsheikh1; Abdelrahman Mohamed amin Sarhan2; Radwa Abdou Mohamed  3; Marwa Mohammed Esawy 4
| ||||
| 1Professor of Clinical and Chemical Pathology, Faculty of Medicine, Zagazig university | ||||
| 2Professor of General Surgery, Faculty of Medicine, Zagazig university | ||||
| 3Resident of Clinical Pathology, Zagazig general hospital | ||||
| 4Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Zagazig University | ||||
| Abstract | ||||
| Background: Breast cancer is considered the most prevalent malignancy among women globally, with a substantial proportion of cases detected only after metastasis has occurred. Traditional serum biomarkers like CA 15-3 and CEA show limited sensitivity and specificity, underscoring the need for more reliable, non-invasive diagnostic tools. Periostin, a matricellular protein known to be overexpressed in tumor microenvironments, has emerged as a potential candidate in cancer diagnostics. The purpose of this study was to evaluate the utility of serum periostin levels as a biomarker for breast cancer diagnosis and for predicting metastasis. Methods: A prospective case-control study was conducted on 72 female participants at Zagazig University Hospitals, divided into three matched groups: group 1 (control group, n=24), group 2 (cancer group, n=24; newly diagnosed breast cancer), and group 3 (benign group, n=24; benign breast lesions). Serum periostin was measured using ELISA and compared with CA 15-3 and CEA levels. Statistical analysis included ROC curve assessments, correlation studies, and multivariate logistic regression. Results: The breast cancer patients had significantly higher serum periostin levels (median 625.3 pg/mL) than benign lesion patients and healthy controls (p<0.001). A cutoff of ≥368.35 pg/mL yielded a sensitivity of 87.5% and specificity of 95.8% (AUC=0.931). Serum periostin also demonstrated strong predictive value for metastasis (cutoff ≥742.4 pg/mL, AUC=0.879), advanced tumor stage (AUC=0.972), and high-grade tumors (AUC=0.8). Serum periostin correlated significantly with tumor size, stage, grade, and HER2 positivity (p<0.05). Conclusion: Serum periostin is significantly elevated in breast cancer patients and demonstrates strong diagnostic and prognostic capabilities. | ||||
| Keywords | ||||
| Serum Periostin; Breast Cancer; Diagnosis; Metastasis; Prediction | ||||
|
Statistics Article View: 52 |
||||
